---
title: Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy
date: '2024-06-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38865661/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240613182158&v=2.18.0.post9+e462414
source: N Engl J Med
description: Indolent CD4+ cytotoxic chimeric antigen receptor (CAR) T-cell lymphoma
  involving the small intestine was diagnosed in a patient who had previously received
  ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy for treatment of myeloma.
  Targeted messenger RNA sequencing revealed the presence of CAR gene product in tumor
  cells. Whole-genome sequencing of samples of tumor and peripheral blood identified
  a single lentiviral insertion site within the second intron of the SSU72 gene. In
  ...
disable_comments: true
---
Indolent CD4+ cytotoxic chimeric antigen receptor (CAR) T-cell lymphoma involving the small intestine was diagnosed in a patient who had previously received ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy for treatment of myeloma. Targeted messenger RNA sequencing revealed the presence of CAR gene product in tumor cells. Whole-genome sequencing of samples of tumor and peripheral blood identified a single lentiviral insertion site within the second intron of the SSU72 gene. In ...